A randomized, double-blinded, placebo-controlled, multi-institutional, cross-over, phase II.5 study of saracatinib (AZD0530), a selective Src kinase inhibitor, in patients with recurrent osteosarcoma ...
Amgen and Takeda's trebananib peptibody missed its overall survival end point in a pivotal ovarian cancer trial, despite promising signals of progression-free survival. The lowdown: Anti-angiogenesis ...
To study the potential pathological role of endogenous angiopoietins in daunorubicin-induced progressive glomerulosclerosis in rats. During DRB-induced glomerulosclerosis, podocyte injury led to a ...
Rituximab Therapy for Patients With Newly Diagnosed, Advanced-Stage, Follicular Grade I Non-Hodgkin's Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group We investigated the ...
Aging causes a reduction of the protein Tie2, a risk factor for increased intraocular pressure and glaucoma. In this experiment, one eye of mice lacking Ang1 and Ang2 was injected with the premixed ...
Aerpio Pharmaceuticals Inc. has "a very different way" of activating Tie2, CEO Joseph Gardner told BioWorld Today. "What I don't know is whether an anti-angiopoietin-2 [Ang2] antibody activates Tie2, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results